Entrada Therapeutics EBIT

The latest EBIT for TRDA is $-170M as of June 2026. That compares with $-97M in the prior-year period — down 76.3% year over year. That is below the sector sector average of $-9.6M. Investors often review this figure alongside Entrada Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TRDA's EBIT moved from $-97M to $-170M — a 76.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Entrada Therapeutics's operating scale or balance-sheet position.

Against its sector companies, TRDA currently prints $-170M for EBIT, while the sector average sits near $-9.6M. That is roughly 1676.8% below the sector mean. Large gaps often invite a closer look at Entrada Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-170M for TRDA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-9.6M. Explore the charts below for those layers of context.

After noting TRDA's EBIT ($-170M), review year-over-year change from $-97M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.